Dodge & Cox recently announced the acquisition of new stake in GSK plc (NYSE:GSK). The institutional investor has increased its shareholding in the Healthcare company by 10.84% to 64.93 million shares with purchase of 6.35 million shares. This fresh investment now brings its stake to 3.17% valued currently at $2.23 billion. In addition, JTC Plc /Private Banking/ raised its holdings by 13.26 million to 17.97 million shares. And Arrowstreet Capital LP has lifted its position by 74.56% or 6.0 million shares – to 14.04 million shares.
With over 3.7 million GSK plc (GSK) shares trading Monday and a closing price of $33.52 on the day, the dollar volume was approximately $123.94 million. The shares have shown a positive half year performance of 5.11% and its price on 03/13/23 gained nearly 0.06%. Currently, there are 2.01B common shares owned by the public and among those 2.00B shares have been available to trade.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 24 analysts who have offered their price forecasts for GSK have a consensus price objective of $40.32. The analysts have set the share’s price value over the next 12 months at a high of $64.43 and a low of $31.22. The average price target is 24.01% above its recent price level and a downside to the estimated low will see the stock lose -7.37% over that period. But an upside of 47.97% will see the stock hit the forecast high price target while median target price for the stock is $38.46.
Insiders at the company have transacted a total of 5 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 5 of these insider trades were purchases, accounting for 15,589 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in GSK plc are Dodge & Cox Stock Fund, Dodge & Cox Balanced Fund, and T Rowe Price International Value. Dodge & Cox Stock Fund owns 45.46 million shares of the company’s stock, all valued at over $1.56 billion. The company bought an additional 4.58 million shares recently to bring their total holdings to about 2.22% of the shares outstanding. Dodge & Cox Balanced Fund bought 0.96 million shares to see its total holdings expand to 5.99 million shares valued at over $205.41 million and representing 0.29% of the shares outstanding. T Rowe Price International Value bought 2259.0 shares to bring its total holdings to over 3.02 million shares at a value of $103.51 million. T Rowe Price International Value now owns shares totaling to 0.15% of the shares outstanding.
Shares of GSK plc (NYSE: GSK) opened at $33.60, up $0.1 from a prior closing price of $33.50. However, the script later moved the day high at 33.81, up 0.06%. The company’s stock has a 5-day price change of -2.70% and -8.42% over the past three months. GSK shares are trading -4.61% year to date (YTD), with the 12-month market performance down to -19.36% lower. It has a 12-month low price of $28.47 and touched a high of $47.82 over the same period. GSK has an average intraday trading volume of 3.93 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -3.95%, -4.50%, and -7.19% respectively.
Institutional ownership of GSK plc (NYSE: GSK) shares accounts for 13.80% of the company’s 2.01B shares outstanding. Mutual fund holders own 4.60%, while other institutional holders and individual stakeholders account for 9.25% and — respectively.
It has a market capitalization of $68.52B and a beta (3y monthly) value of 0.69. The stock’s trailing 12-month PE ratio is 12.87, while the earnings-per-share (ttm) stands at $2.60. The company has a PEG of 2.43 and a Quick Ratio of 0.70 with the debt-to-equity ratio at 2.42. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.49% over the week and 1.24% over the month.
Analysts forecast that GSK plc (GSK) will achieve an EPS of $0.9 for the current quarter, $0.93 for the next quarter and $3.93 for 2024. The lowest estimate earnings-per-share for the quarter is $0.9 while analysts give the company a high EPS estimate of $0.9. Comparatively, EPS for the current quarter was $1.09 a year ago. Earnings per share for the fiscal year are expected to decrease by -42.60%, and 7.70% over the next financial year. EPS should shrink at an annualized rate of 5.30% over the next five years, compared to 28.60% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 24 brokerage firm advisors rate GSK plc (GSK) as a “Moderate Buy” at a consensus score of 2.80. Specifically, 9 Wall Street analysts polled rate the stock as a buy, while 12 of the 24 advise that investors “hold,” and 2 rated it as a “Sell.”
Credit Suisse on their part issued Neutral rating on September 15, 2022.
Leave a Reply